Prexigebersen clinical trials
How each study uses prexigebersen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the prexigebersen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Bio-Path Holdings, Inc. (4)
Often tested with
Tested in the same studies.
Growth Factor Receptor-Bound Protein 2 (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test prexigebersen.
- Jul 2027BP1001-A in Patients With Advanced or Recurrent Solid TumorsPhase 1 · Bio-Path Holdings, Inc.
Studies
Open first, then newest update. How each study uses prexigebersen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- BP1001-A in Patients With Advanced or Recurrent Solid TumorsRecruitingPhase 1Bio-Path Holdings, Inc.NCT04196257Written as BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)How we know
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLRecruitingPhase 2Bio-Path Holdings, Inc.NCT02781883Written as BP1001 plus decitabineHow we know
- Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSCompletedPhase 1Bio-Path Holdings, Inc.NCT01159028Written as BP1001How we know
- Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSWithdrawnPhase 1/2Bio-Path Holdings, Inc.NCT02923986Written as BP1001 (varying dose)How we know
Codes
What other systems call prexigebersen · ClinicalTrials.gg INT015729
- UNII (FDA) 8W1O4Y961BPREXIGEBERSENOne source FDA
- NCI Thesaurus C91736PrexigebersenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8W1O4Y961B | PREXIGEBERSEN | One source FDA |
| NCI Thesaurus | C91736 | Prexigebersen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.